Accumulating evidence supports a causal role of hypertension for cognitive decline above and beyond its relationship to frank stroke. Hypertension-associated pathologic changes in the brain and its vasculature include vascular remodeling, impaired cerebral autoregulation, cerebral microbleeds, white matter lesions, unrecognized lacunar infarcts, and Alzheimer-like changes such as amyloid angiopathy and cerebral atrophy. White matter lesions and retinal vascular changes, both of which can be imaged noninvasively, may reveal the general condition of the cerebral vasculature or the presence of arteriosclerotic or hypertensive encephalopathy. These noninvasive indicators may also identify a subgroup in whom infarct prevention, particularly via blood pressure reduction, is of paramount importance. Optimal control of blood pressure on a population-wide basis, but particularly in those prone to cognitive loss, is thus a critically important but as yet elusive goal that should be fully exploited for its potential to reduce future cognitive impairment.
This is a preview of subscription content, log in to check access.
Buy single article
Instant access to the full article PDF.
Price includes VAT for USA
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
This is the net price. Taxes to be calculated in checkout.
References and Recommended Reading
Elias MF, Wolf PA, D’Agostino RB, et al.: Untreated blood pressure level is inversely related to cognitive functioning: the Framingham Study. Am J Epidemiol 1993, 138:353–364.
Knopman D, Boland LL, Mosley T, et al.: Cardiovascular risk factors and cognitive decline in middle-aged adults: the Atherosclerosis Risk in Communities (ARIC) Study investigators. Neurology 2001, 56:42–48.
Zhu L, Viitanen M, Guo Z, et al.: Blood pressure reduction, cardiovascular diseases, and cognitive decline in the Mini-Mental State Examination in a community population of normal very old people: a three-year follow-up. J Clin Epidemiol 1998, 51:385–391.
Seux ML, Thijs L, Forette F, et al.: Correlates of cognitive status of old patients with isolated systolic hypertension: the Syst-Eur Vascular Dementia Project. J Hypertens 1998, 16:963–969.
Rigaud AS, Olde-Rikkert MGM, Hanon O, et al.: Antihypertensive drugs and cognitive function. Curr Hypertens Rep 2002, 4:211–215. In this review, the authors conclude that antihypertensive treatment has been shown to reverse the increased risk of cerebrovascular morbidity and mortality associated with hypertension, and also to decrease the risk of cognitive impairment and dementia. The mechanisms by which various classes of antihypertensive drugs prevent cognitive decline and their relative benefits remain unclear.
Walstein SR, Jennings JR, Ryan CM, et al.: Hypertension and neuropsychological performance in men: Interactive effects of age. Health Psychol 1996, 15:102–109.
Erkinjuntti T: Subcortical vascular dementia. Cerebrovasc Dis 2002, 13(Suppl 2):58–60.
Desmond DW: Cognition and white matter lesions. Cerebrovasc Dis 2002, 13(Suppl 2):53–57.
Ross GW, Launer LJ, Petrovitch H, et al.: The association between mid-life blood pressure and dementia: the Honolulu-Asia Aging Study. Neurology 1998, 50:A229.
Anstey K, Christensen H: Education, activity, health, blood pressure and apolipoprotein E as predictors of cognitive change in old age: a review. Gerontology 2000, 46:163–177. Findings from longitudinal studies are generally consistent with crosssectional reports showing associations of education, hypertension, cardiovascular and cerebrovascular disease, apolipoprotein E, and possibly physical activity with cognitive change in late adulthood.
MacMahon S, Peto R, Cutler J, et al.: Blood pressure, stroke, and coronary heart disease. Part 1, Prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet 1990, 335:765–774.
Collins R, Peto R, MacMahon S, et al.: Blood pressure, stroke, and coronary heart disease. Part 2. Short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet 1990, 335:827–838.
Brown RD, Whisnant JP, Sicks JD, et al.: Stroke incidence, prevalence, and survival. Secular trends in Rochester, Minnesota, through 1989. Stroke 1996, 27:373–380.
Cotran RS, Kumar V, Collins T: Robbins Pathologic Basis of Disease, edn 6. Philadelphia: WB Saunders; 1999.
Guo Z, Viitanen M, Fratiglioni L, Winblad B: Blood pressure and dementia in the elderly: epidemiologic perspectives. Biomed Pharmacother 1997, 51:68–73.
Semplicini A, Maresca A, Sartori M, et al.: Hypertension and cerebrovascular diseases: a specific role of vascular protection for the prevention of dementia. J Cardiovasc Pharmacol 2001, 38(Suppl 2):S79-S82.
Mulvany MJ: Small artery remodeling and significance in the development of hypertension. New Physiol Sci 2002, 17:105–109. Remodeling of resistance vessels seen in hypertension depends not only on blood pressure, but also on blood flow and hormonal environment. Correction of these remodeling changes is seen in response to antihypertensive therapies that cause vasodilation (angiotensinconverting enzyme inhibitors), but not with those that decrease cardiac output (β-blockers).
Kalaria RN: Small vessel disease and Alzheimer’s dementia: pathological considerations. Cerebrovasc Dis 2002, 13(Suppl 2):48–52. This article describes small vessel changes commonly seen in Alzheimer’s disease cases including amyloid-β-associated cerebral amyloid angiopathy, vascular smooth muscle cell atrophy, endothelial degeneration, vascular basement membrane alterations, hyalinosis, and fibrosis. Perivascular changes including denervation, macro- and microinfarctions, hemorrhages, lacunes, and ischemic white matter changes are also discussed.
Wong TY, Klein R, Sharrett AR, et al.: Retinal microvascular abnormalities and cognitive impairment in middle-aged persons: the Atherosclerosis Risk in Communities Study. Stroke 2002, 33:1487–1492.
Kalaria RN: The blood-brain barrier and cerebral microcirculation in Alzheimer disease. Cerebrovasc Brain Metab Rev 1992, 4:226–260.
Paulson OB, Standgaard S: Hypertensive disease and cerebral circulation. In Hypertension: Pathophysiology, Diagnosis and Treatment. Edited by Laragh JH, Brenner BM. New York: Raven Press; 1995:445–463.
Kato H, Izumiyama M, Izumiyama K, et al.: Silent cerebral microbleeds on T2*-weighted MRI; correlation with stroke subtype, stroke recurrence, and leukoaraiosis. Stroke 2002, 33:1536–1540.
Kidwell CS, Saver JL, Villablanca JP, et al.: Magnetic resonance imaging detecton of microbleeds before thrombolysis: an emerging application. Stroke 2002, 33:95–98.
Pantoni L, Garcia JH: The significance of cerebral white matter abnormalities 100 years after Binswanger’s report: a review. Stroke 1995, 26:1293–1301.
Manolio TA, Furberg CD: Age as a predictor of outcome: what role does it play? Am J Med 1992, 92:1–6.
Longstreth WT Jr, Manolio TA, Arnold A, et al.: Clinical correlates of white matter findings on cranial magnetic resonance imaging of 3301 elderly people: the Cardiovascular Health Study. Stroke 1996, 27:1274–1282.
Englund E: Neuropathology of white matter lesions in vascular cognitive impairment. Cerebrovasc Dis 2002, 13(Suppl 2):11–15. The authors describe the histopathologic spectrum and neuroimaging correlates of white matter lesions seen in vascular cognitive impairment. White matter changes range from focal infarcts, the result of an acute reaction to ischemia, to diffuse white matter lesions reflecting longerterm adjustment to either acutely altered perfusion or to chronic cerebral hypoperfusion or hypoxia.
Englund E: Neuropathology of white matter disease: parenchymal changes. In The Matter of White Matter. Clinical and Pathophysiological Aspects of White Matter Disease Related to Cognitive Decline and Vascular Dementia. Edited by Pantoni L, Inzitari D, Wallin A. Utrecht: Academic Pharmaceutical Productions; 2000:223–246.
Pantoni L: Pathophysiology of age-related cerebral white matter changes. Cerebrovasc Dis 2002, 13(Suppl 2):7–10.
DeCarli C, Murphy DGM, Tran M, et al.: The effect of white matter hyperintensity volume on brain structure, cognitive performance and cerebral metabolism in 51 healthy adults. Neurology 1995, 45:2077–2084.
Schmidt R, Schmidt H, Kapeller P, et al.: Evolution of white matter lesions. Cerebrovasc Dis 2002, 13(Suppl 2):16–20. Results from the Austrian Stroke Prevention Study, a 3-year cohort study of 273 participants (mean age, 60 years), are summarized, including the finding that only baseline diastolic blood pressure and the presence of early confluent or confluent white matter hyperintensities at baseline predicted progression of white matter hyperintensities over 3 years. Genetic association analyses suggest that genes involved in oxidative defense and in the renin-angiotensin system may be involved in the etiology of white matter lesions.
Fisher CM: The arterial lesions underlying lacunes. Acta Neuropathol 1969, 3:1–15.
Longstreth WT, Diehr P, Manolio TA, et al., for the Cardiovascular Health Study Collaborative Research Group: Cluster analysis and patterns of findings on cranial magnetic resonance imaging of the elderly: the Cardiovascular Health Study. Arch Neurol 2001, 58:635–640.
Pantoni L: Cerebral white matter ischemia and anoxia: data from experimental models. In The Matter of White Matter. Clinical and Pathophysiological Aspects of White Matter Disease Related to Cognitive Decline and Vascular Dementia. Edited by Pantoni L, Inzitari D, Wallin A. Utrecht: Academic Pharmaceutical Productions; 2000:377–388.
Erkinjuntti T, Haltia M, Palo J, Paetu A: Accuracy of the clinical diagnosis of vascular dementia: a prospective clinical and post-mortem neuropathological study. J Neurol Neurosurg Psychiatr 1988, 51:1037–1044.
Petrovitch H, White LR, Izmirilian G, et al.: Midlife blood pressure and neuritic plaques, neurofibrillary tangles, and brain weight at death: the HAAS. Neurobiol Aging 2000, 21:57–62.
Neuropathology Group of the Medical Research Council Cognitive Function and Aging Study (MRC CFAS): Pathological correlates of late-onset dementia in a multicentre, community-based population in England and Wales. Lancet 2001, 357:169–175.
Snowdon DA, Greiner LH, Mortimer JA, et al.: Brain infarction and the clinical expression of Alzheimer’s disease. The Nun Study. JAMA 1997, 277:813–817.
Kalaria RN: The role of cerebral ischemia in Alzheimer’s disease. Neurobiol Aging 2000, 21:321–330. In this review, the author presents findings suggesting that vascular risk factors for cerebrovascular disease and stroke in the elderly also increase the risk of developing Alzheimer’s disease, supporting the hypothesis that cerebral ischemia or hypoperfusion may promote Alzheimer-type changes in the brain.
Loscalzo J, Balaban R, Becker LB, et al.: Task force on strategic research direction: basic science subgroup key science topics report. Circulation 2002, 106:e149-e161.
Strassburger TL, Lee HC, Daley EM, et al.: Interactive effects of age and hypertension on volumes of brain structures. Stroke 1997, 28:1410–1417.
Salerno JA, Grady C, Mentis M, et al.: Brain metabolic function in older men with chronic essential hypertension. J Gerontol Biol Sci Med Sci 1995, 50:M147-M154.
Psaty BM, Furberg CD, Kuller LH, et al.: Association between blood pressure level and the risk of myocardial infarction, stroke, and total mortality: the cardiovascular health study. Arch Intern Med 2001, 161:1183–1192.
Skoog I, Andreasson LA, Landahl S, Lernfelt B: A populationbased study on blood pressure and brain atrophy in 85-yearolds. Hypertension 1998, 32:404–409.
Burke WJ, Coronado PG, Schmitt CA, et al.: Blood pressure regulation in Alzheimer=s disease. J Auton Nerv Syst 1994, 48:65–71.
Vinters HV: Cerebral amyloid angiopathy. A critical review. Stroke 1987, 18N:311–324.
Pfeifer LA, White LR, Ross GW, et al.: Cerebral amyloid angiopathy and cognitive function: The HAAS autopsy study. Neurology 2002, 58:1629–1634.
Walker LC, Durham RA: Cerebrovascular amyloidosis: experimental analysis in vitro and in vivo. Histol Histopathol 1999, 14:827–837.
de la Torre JC: Critically attained threshold of cerebral hypoperfusion: the CATCH hypothesis of Alzheimer’s pathogenesis. Neurobiol Aging 2000, 21:331–342.
Thomas T, Thomas G, McLendon C, et al.: Beta-amyloid-mediated vasoactivity and vascular endothelial damage. Nature 1996, 380:168–171.
About this article
Cite this article
Manolio, T.A., Olson, J. & Longstreth, W.T. Hypertension and cognitive function: Pathophysiologic effects of hypertension on the brain. Current Science Inc 5, 255–261 (2003). https://doi.org/10.1007/s11906-003-0029-6
- White Matter
- Vascular Dementia
- White Matter Lesion
- Cerebral Amyloid Angiopathy
- White Matter Change